Ferring counsel departs due to Swiss role

Moshinsky, Ben
March 2006
Lawyer;3/20/2006, Vol. 20 Issue 11, p8
Trade Publication
The article reports on the departure of lawyer Patricia Barclay from Ferring Pharmaceutical Inc. after the firm relocated from Copenhagen to Wallisellen, Switzerland. Barclay is determined not to move with the company headquarters, which could result Ferring without a general counsel for much of the year. Ferring would choose to hire from competitors in the pharmaceutical market. The firm has invested 90 million euro to construct its new Swiss headquarters.


Related Articles

  • Savient sells its biologics.  // Chemical Market Reporter;3/28/2005, Vol. 267 Issue 13, p2 

    Reports that Savient Pharmaceuticals Inc. has shed its global biologics manufacturing operations to two subsidiaries of Lausanne, Switzerland-based biopharmaceutical Ferring Holding SA. Amount that will be paid by Ferring; Global rights gained by Ferring to human growth hormone and other products.

  • Pharma & Fine Chemicals: Market Briefs.  // Chemical Market Reporter;09/20/99, Vol. 256 Issue 12, p12 

    Presents news briefs from the pharmaceuticals and fine chemicals industries as of September 20, 1999. Acquisition of marketing and distribution rights for Sanofi-Sythelabo's Dynabac in the United States by Muro Pharmaceutical Inc.; Marketing approval received by Nordisk AS for its liquid growth...

  • Parallel Trader Plays Hardball. Gopal, Kevin // Pharmaceutical Executive;Apr2002, Vol. 22 Issue 4, p21 

    Focuses on the lawsuit filed by German pharmaceutical company Ferring against parallel-trader Erim-Pharm (E-P). Information on Ferring's voluntary withdrawal of marketing authorization for its desmopressin spray, Minirin; Comments from observers on the intention of Ferring to prevent parallel...

  • Pipeline.  // Medical Marketing & Media;Aug2007, Vol. 42 Issue 8, p10 

    The article offers news briefs related to pharmaceutical industry in the U.S. The Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) submitted by Barr Laboratories Inc. to market the generic version of Dostinex. Ferring Pharmaceuticals announces the...

  • PhRMA Goes Biotech.  // Pharmaceutical Technology;Jan2010, Vol. 34 Issue 1, p24 

    The article reports that several new pharmaceutical companies have joined the Pharmaceutical Research and Manufacturers of America (PhRMA). It mentions that the new companies who have joined include Cubist Pharmaceuticals Inc. of Lexington, Massachusetts, OSI Pharmaceuticals Inc. of Melville,...

  • Update.  // Medical Marketing & Media;Jun2005, Vol. 40 Issue 6, p9 

    This article presents news briefs related to the pharmaceutical industry. Apprise Media LLC enters the market for healthcare b-to-b publishing with its purchase of Canon Communications PLC from private equity firm Veronis Suhler Stevenson in a deal estimated at $200 million. Ferring...

  • News Watch.  // European Chemical News;6/6/2005, Vol. 82 Issue 2150, p25 

    Presents news briefs concerning pharmaceutical industry as of June 2005. Research agreement signed by Codexis with Bristol-Myers Squibb to improve biocatalyst activity for a new Bristol-Myers Squibb candidate; Commercial license agreement signed by Crucell and DSM Biologics with Ferring...

  • Drugs company makes false claims over bedwetting drug. Gould, Mark // BMJ: British Medical Journal (International Edition);1/5/2002, Vol. 324 Issue 7328, p9 

    Reports that the Prescription Medicines Code of Practice Authority has ordered Ferring Pharmaceutical to withdraw literature about its bedwetting drug desmopressin. How pediatrician Delia Elliott sent a letter to the Authority expressing concerns about false claims about the effectiveness of...

  • Albireo, Ferring Ink Deal for Constipation Drug Elobixibat. Sheridan, Cormac // BioWorld International;7/5/2012, Vol. 17 Issue 27, p2 

    The article reports that Albireo AB has given rights to Ferring Pharmaceuticals SA for constipation drug elobixibat which includes milestones and tiered double-digit royalties. Ferring has also rights to the drug sold in other countries other than Japan, South Korea, Thailand, Indonesia and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics